Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined chronological changes in gut microbiota composition among children with acute lymphoblastic leukemia (ALL) using 16S ribosomal RNA sequencing. The researchers tracked microbiota profiles at multiple time points: before chemotherapy began, during treatment, and after chemotherapy was completed. The goal was to determine whether disruptions to the gut microbiota caused by leukemia and its treatment are reversible once therapy ends and disease remission is achieved.
Who was studied?
The study population was a group of paediatric patients diagnosed with acute lymphoblastic leukemia, followed longitudinally through the course of their chemotherapy treatment. Their gut microbiota profiles were compared against those of age- and ethnicity-matched healthy children serving as controls. The abstract does not provide an exact number of participants.
What were the most important findings?
Before chemotherapy started, children with ALL showed greater inter-individual variability in gut microbiota composition compared to healthy controls, along with enrichment of bacteria from the Bacteroidetes phylum and the Bacteroides genus. Once chemotherapy commenced, the relative abundance of Bacteroides decreased. Following cessation of chemotherapy, the gut microbiota composition shifted back toward a profile resembling that of the healthy control group.
What are the greatest implications of this study?
The findings suggest that chemotherapy-associated disruption of the gut microbiota in pediatric ALL patients is not necessarily permanent and can be restored after treatment ends. This raises the possibility that gut microbiota status could serve as a marker to monitor recovery alongside disease remission. It also points to Bacteroides dynamics as a specific feature worth further investigation in the context of childhood leukemia and chemotherapy exposure.